skip to main content

Polymyalgia Rheumatica — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

HardSoft Tissue RheumatologyPolymyalgia RheumaticaSCE Rheumatology

A postmenopausal woman at very high fracture risk completes 12 monthly doses of romosozumab without cardiovascular events. Which plan best preserves the skeletal benefit?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Stop romosozumab after month 12 and transition to an antiresorptive treatment

Explanation lettering: B = shown as A · A = shown as B

A is correct. Romosozumab is 210 mg once monthly, delivered as two 105 mg injections, for a fixed 12-month course. The SmPC recommends transition to antiresorptive therapy afterwards to extend the benefit. Continuing or spacing romosozumab beyond the authorised course is unsupported, and routine observation permits the gained effect to diminish.

Reference: Evenity 105 mg pre-filled pen SmPC: https://www.medicines.org.uk/emc/product/10956/smpc